Targeting Post-translational Modifications on Tau as a Therapeutic Strategy for Alzheimer's Disease
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder that causes early memory impairment, followed by profound progressive cognitive decline, and eventually death. Neurofibrillary tangles (NFTs) are one of the histopathological hallmarks of AD. NFTs are deposits of insoluble aggregates of the microtubule-binding protein tau, left behind following neuronal loss. Intracellular aggregates of tau, either in soluble or insoluble forms, are thought to disrupt cellular machinery and synaptic function and ultimately lead to neuronal death. As the ultimate pathological endpoint in AD is neuronal loss, there is significant interest in understanding the causes of tau aggregation and deposition in the brain as a potential therapeutic avenue for AD. Post-translational modifications on tau are thought to be an important regulatory mechanism that may contribute to the propensity of tau to aggregate and form NFTs. In addition to phosphorylation, numerous other post-translational modifications have been observed on tau protein. The mechanisms that cause aggregation of tau are unknown, but it is likely that post-translational modifications other than phosphorylation also regulate this process. This review will discuss several post-translational modifications of tau and their roles in modulation of tau function and aggregation in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538
Jin, M., Shepardson, N., Yang, T., Chen, G., Walsh, D., & Selkoe, D. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017033108 · Cited by 876 · cited 1×
“Cellular toxicity and deleterious synaptic effects have been attributed to beta-amyloid peptides, in monomer or aggregated soluble forms and in insoluble plaque (Allsop & Hardy, 1991; Glabe & Kayed, 2006; Gravina et al., 1995; Jin et al., 2011).”
BackgroundO-GlcNAcylation regulates phosphorylation of tau: A mechanism involved in Alzheimer's disease
Liu, F., Iqbal, K., Grundke-Iqbal, I., Hart, G. W., & Gong, C.-X. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400348101 · Cited by 775 · cited 2×
“In one report, overall protein O-GlcNAcylation in brains from AD patients is 22% lower than in control individuals (Liu et al., 2004).”
BackgroundThe acetylation of tau inhibits its function and promotes pathological tau aggregation
Cohen, T. J., Guo, J. L., Hurtado, D. E., Kwong, L. K., Mills, I. P., Trojanowski, J. Q., & Lee, V. M. Y. (2011) · Nature Communications · doi:10.1038/ncomms1255 · Cited by 724 · cited 7×
“Furthermore, there are potential acetylation sites at Lys 281 and Lys 369 as well (Cohen et al., 2011).”
BackgroundInfluentialA potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo
Yuzwa, S. A., Macauley, M. S., Heinonen, J. E., Shan, X., Dennis, R. J., He, Y., Whitworth, G. E., Stubbs, K. A., McEachern, E. J., Davies, G. J., et al. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.96 · Cited by 717 · cited 2×
“…phosphorylated epitopes on tau have been shown to be modulated in this way under various conditions, including pS199, pS202, pS205, pT212, pS214, pT231, pS262, pS396, and pS422 (Lefebvre et al., 2003; Li et al., 2006; Liu et al., 2004; Liu et al., 2009; Robertson et al., 2004; Yuzwa et al., 2008).”
BackgroundEvolution of the neuropathology of Alzheimer's disease
Braak, H., & Braak, E. (1996) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1996.tb05866.x · Cited by 710
Ramsden, M., Kotilinek, L., Forster, C., Paulson, J., McGowan, E., SantaCruz, K., Guimaraes, A., Yue, M., Lewis, J., Carlson, G., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3279-05.2005 · Cited by 702 · cited 1×
“In several transgenic rodent models, generation of aggregated tau has been shown to be accompanied by robust neurodegeneration (Adams et al., 2009; Mocanu et al., 2008; Ramsden et al., 2005).”
BackgroundAmyloid β Protein (Aβ) in Alzheimeri's Disease Brain
Gravina, S. A., Ho, L., Eckman, C. B., Long, K. E., Otvos, L., Younkin, L. H., Suzuki, N., & Younkin, S. G. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.13.7013 · Cited by 676
Biological selectivity and functional aspects of protein tyrosine nitration
Ischiropoulos, H. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00814-3 · Cited by 500
Liu, F., Shi, J., Tanimukai, H., Gu, J., Gu, J., Grundke-Iqbal, I., Iqbal, K., & Gong, C.-X. (2009) · Brain · doi:10.1093/brain/awp099 · Cited by 439 · cited 2×
“…phosphorylated epitopes on tau have been shown to be modulated in this way under various conditions, including pS199, pS202, pS205, pT212, pS214, pT231, pS262, pS396, and pS422 (Lefebvre et al., 2003; Li et al., 2006; Liu et al., 2004; Liu et al., 2009; Robertson et al., 2004; Yuzwa et al., 2008).”
Background
Cited by
Alzheimer’s disease: pathogenesis, diagnostics, and therapeutics
Tiwari, S., Atluri, V., Kaushik, A., Yndart, A., & Nair, M. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s200490 · Cited by 1,308
Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation
Yuzwa, S. A., Shan, X., Macauley, M. S., Clark, T., Skorobogatko, Y., Vosseller, K., & Vocadlo, D. J. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.797 · Cited by 611
GWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimer’s Disease
Cruchaga, C., Kauwe, J. S. K., Harari, O., Jin, S. C., Cai, Y., Karch, C. M., Benitez, B. A., Jeng, A. T., Skorupa, T., Carrell, D., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.02.026 · Cited by 383
“These changes are thought 264 Neuron 78, 256–268, April 24, 2013 ª2013 Elsevier Inc. to play an important role in tau-related pathogenesis (Farı́as et al., 2011; Marcus and Schachter, 2011).”
BackgroundDisease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Golde, T. E. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01201-2 · Cited by 119
Ball, M. J., Lukiw, W. J., Kammerman, E. M., & Hill, J. M. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.07.005 · Cited by 89
Metadata
- Authors
- Marcus, J. N., & Schachter, J.
- Venue
- Journal of Neurogenetics
- Publisher
- Informa UK Limited
- Published
- 2011-11-17
- Volume
- 25
- Issue
- 4
- Pages
- 127-133
- ISSN
- 0167-7063 (ISSN-L)
- 1563-5260
- OpenAlex
- W2023241993
- Cited by
- 50
- References
- 15
- FWCI
- 1.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting Post-translational Modifications on Tau as a Therapeutic Strategy for Alzheimer's Disease. https://app.cochat.ai/papers/10.3109/01677063.2011.626471
- The paper
- Marcus, J. N., & Schachter, J. (2011). Targeting Post-translational Modifications on Tau as a Therapeutic Strategy for Alzheimer's Disease. Journal of Neurogenetics. https://doi.org/10.3109/01677063.2011.626471
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.